TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00162305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-512148
Description: Capsules, Oral, 100 mg, Once daily, 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-512148
Description: Capsules, Oral, 25 mg, Once daily, 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-512148
Description: Capsules, Oral, 5 mg, Once daily, 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, Once daily, 14 days.
Study: NCT01341431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bee venom
Description: 12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bee venom
Description: 12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
Study: NCT04415216

Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)

Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
Study: NCT03095924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT04218916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola Rosea Capsules
Description: 0.28g per capsule, 0.56g once (2 capsules), three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules once, three times a day
Study: NCT03369106

Intervention type: OTHER
Intervention: Composite severity score calculation
Description: Neurological examination, cognitive testing, and MRI exam
Study: NCT02041078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrahepatic division of the right hepatic vein.
Description: Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extrahepatic vein division
Description: Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
Study: NCT01372696

Intervention type: OTHER
Group type: OTHER
Intervention: Sample of polyp
Description: A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
Study: NCT03485157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micronized dHACM
Description: Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of 1 mL 0.9% Sodium Chloride, USP
Study: NCT01888016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial manipulation
Description: • 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard physiotherapies treatment
Description: 10 standard treatments in 2 weeks~* Deltoid and infraspinatus muscles electrotherapy~* Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~* Scar massage~* Upper limb, cervical spine and scapula massages~* Passive and assisted/active shoulder mobilization exercises~* Scapula micro-mobilizations~* Gleno-humeral decoaptation~* Elbow, wrist and hand active mobilization~* Proprioceptive exercise with and without the aid of the mirror

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard physiotherapies treatment
Description: 10 standard treatments in 2 weeks~* Deltoid and infraspinatus muscles electrotherapy~* Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~* Scar massage~* Upper limb, cervical spine and scapula massages~* Passive and assisted/active shoulder mobilization exercises~* Scapula micro-mobilizations~* Gleno-humeral decoaptation~* Elbow, wrist and hand active mobilization~* Proprioceptive exercise with and without the aid of the mirror
Study: NCT01135966

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resistance training program
Description: Conventional resistance training program is followed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole body vibration resistance training program
Description: WBV training on FITVIBE
Study: NCT03558217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collared Femoral Implant
Description: Corail collared femoral implant for total hip arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collarless Femoral Implant
Description: Corail collarless femoral implant for total hip arthroplasty
Study: NCT01435161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine,
Description: Nifedipine 30-60mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan 80-160mg/day
Study: NCT01227057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding
Description: The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
Study: NCT04980261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ORIF + FD BHA/Secretome
Description: Patients will undergo an ORIF procedure and subsequently receive freeze-dried bovine hydroxyapatite/secretome composite implantation.
Study: NCT04875130

Intervention type: DIAGNOSTIC_TEST
Intervention: blood samples
Description: Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
Study: NCT01227057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Case management
Study: NCT00458549

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study: NCT01480102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A-Paravertebral block
Description: Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B- No block
Description: direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
Study: NCT04164069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03314454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beer
Description: Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beer
Description: Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beer
Description: Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beer
Description: Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videotaped drinking session
Description: Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videotaped drinking session
Description: Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
Study: NCT03069443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IHG home training
Description: Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
Study: NCT01577420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology Sessions
Description: One session per week performed by certified reflexologist for four consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sessions
Description: One session per week performed by research aide for four consecutive weeks.
Study: NCT02597673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
Study: NCT01072097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg/day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 months
Study: NCT04183842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LACIME Anti-hangover
Description: LACIME Anti-hangover contains the following excipients:~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~LACIME Anti-hangover contains the following plant extracts and vitamin:~* Curcuma longa rhizome extract (Curcuma),~* Panax quinquefolius extract (Ginseng panax),~* Malpighia punicifolia extract (Acerola),~* Silybum marianum extract (Milk thistle),~* Desmodium adscendens extract (Desmodium),~* Pyridoxine chlorhydrate (Vitamin B6).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the following excipients :~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~Placebo contains :~- Carrot juice
Study: NCT02434627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate
Description: Patients will be given sodium nitrate daily in the form of beetroot juice.
Study: NCT02632110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to face prior to light treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to face prior to light treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to face prior to light treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to face prior to light treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to face prior to light treatment
Study: NCT01128530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-32729463
Description: 250 mg tablet twice daily
Study: NCT03082495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
Study: NCT01128530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: 600 mg tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-32729463 placebo
Description: 1 placebo tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid placebo
Description: 1 placebo tablet, twice daily
Study: NCT01492218

Intervention type: DRUG
Intervention: biphasic human insulin 30
Description: Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
Study: NCT02148133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag 12.5 mg
Description: White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg
Description: White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
Study: NCT02668263

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery alone
Description: Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery and Drain(s)
Description: Drains inserted as per standard practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery and Quilting Sutures
Description: Quilting sutures to mastectomy flaps
Study: NCT03710317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
Study: NCT02983032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBTI
Description: 3 group sessions over 4 weeks
Study: NCT00724620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (SCH 054031)
Description: All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (SCH 054031)
Description: All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
Study: NCT02427256

Intervention type: DEVICE
Intervention: Topcon Specular Microscope SP-1P

Intervention type: DEVICE
Intervention: Topcon Specular Microscope SP-1P

Intervention type: DEVICE
Intervention: Topcon Specular Microscope SP-1P

Intervention type: DEVICE
Intervention: Konan Specular Microscope CELLCHEK XL

Intervention type: DEVICE
Intervention: Konan Specular Microscope CELLCHEK XL

Intervention type: DEVICE
Intervention: Konan Specular Microscope CELLCHEK XL
Study: NCT03811678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily
Study: NCT03314454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videotaped drinking session
Description: Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videotaped drinking session
Description: Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
Study: NCT03811678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily
Study: NCT04034888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEX
Description: HEX is a customized exercise program with components including: 1) controlled flexibility movements; 2) progressive ADL training focusing on bed mobility, bed to chair transfers, and indoor walking; 3) task-specific seated resistance training to improve ability to get out of bed and; 4) and balance exercises. Participants will be expected to perform their HEX program at least 2 times/week in their home and all individualized exercise sessions will be supervised by an Exercise Physiologist. Each exercise has four levels of difficulty, which will be progressed as tolerated throughout the 12-weeks. Seated resistance exercises were designed to target all the major muscle groups and will include the following: arm curls, shoulder raises (lateral/front), overhead arm raise, wrist curls, leg extensions, hip flexion, hip ab/adduction, sit-to-stands, torso rotation, and marching.
Study: NCT02734628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)
Description: 30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
Study: NCT00746811

Intervention type: DRUG
Group type: OTHER
Intervention: P-OM3
Description: 4 grams/day - 4 one gram capsules
Study: NCT02734628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Bepanthen® ointment without active ingredient dexpanthenol
Study: NCT01597154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counselling
Description: Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
Study: NCT00770965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Study: NCT00746811

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 4 grams/day - 4 one gram capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 4 grams/day - 4 one gram capsules
Study: NCT04094298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 Injection
Description: One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
Study: NCT00770965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02371746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV515-3 Travoprost XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV515-3 Travoprost XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV515-1 Travoprost XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV515-3-2 Travoprost XR
Study: NCT03193619

Intervention type: DEVICE
Intervention: PTA (UltraScore Focused Force PTA Balloon)
Description: Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated.
Study: NCT03811678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangdaprevir Sodium Tablet
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablet，administered orally once daily